In Brief: Sanofi
Executive Summary
Sanofi: Company halts development of Skelid (tiludronate) for osteoporosis following disappointing results in Phase III clinical trials. "In the targeted indication and at the doses tested, tiludronate does not provide sufficient benefit in the treatment of vertebral fractures in women with postmenopausal osteoporosis," Sanofi said. Results from Phase IIb studies in osteoporosis being conducted in Japan at different doses by Sanofi/Meiji-Seika will be available by year end, the company said. Skelid was approved for Paget's disease in March...